Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 37 recruiting now early-phase tilt #50 of 28,707 conditions

Rheumatoid Arthritis: early-phase trial registry

37 of 199 indexed Rheumatoid Arthritis trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #50 of 28,707 conditions by registered trial count.

199 US clinical trials · 37 currently recruiting · #50 of 28,707 conditions by registered trial count

Rheumatoid Arthritis: 199 US clinical trials tracked, 37 recruiting.

Rheumatoid Arthritis is the subject of 199 registered US clinical trials on ClinicalTrials.gov, 37 of them currently open to new participants. 32 are in Phase 3-4 (later-stage) and 77 in Phase 1-2 (earlier-stage). The most active sponsor is Zimmer Biomet, running 13 of these trials.

Enrollment posture brief

Registry condition rheumatoid-arthritis

OPEN 37 | RECR 19% | LATE 32 | EARLY 77 | RANK #50 | SPON 13

Nearest open-share peer: Leukemia (19% recruiting · 274 trials)

Solid Tumor52.8%Type 1 Diabetes39.7%Glioblastoma39%Overweight25.3%Rheumatoid Arthritis (this)19%
Open-enrollment share among volume-matched conditions near Rheumatoid Arthritis

Rheumatoid Arthritis lists 37 open slots (19% of 199 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Rheumatoid Arthritis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Rheumatoid Arthritis is recruiting below its size-band peers.

    37 of 199 indexed trials (18.6%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Rheumatoid Arthritis trials is spread across many organizations.

    Zimmer Biomet accounts for 13 of 199 trials (6.5%). 114 distinct sponsors appear on at least one study for this condition label.

  3. Typical Rheumatoid Arthritis enrolment sits around 154 participants.

    Median target enrolment is 154 among the 198 trials that report a genuine target (sentinel values excluded). 78 of those (39.4%) plan for fewer than 100 participants.

  4. Rheumatoid Arthritis research is mostly interventional.

    154 interventional and 45 observational studies make up this index (77.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 133Phase 244Phase 325Phase 47

Open and recent trials

199 total, page 3 of 4

COMPLETED Phase 3 350 participants

Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra®) Therapy in Patients With Active Rheumatoid Arthritis

Amgen

NCT00650078

COMPLETED Phase 2 300 participants

Effects of MEDI-522 On Disease Activity and Progression of Joint Damage in Patients With Active Rheumatoid Arthritis Suboptimally Responding to Methotrexate

MedImmune

NCT00069017

COMPLETED NA 286 participants

Enhancing Patient Ability to Understand and Utilize Complex Information Concerning Medication Self-management

University of North Carolina, Chapel Hill

NCT02820038

COMPLETED Phase 2 280 participants

Pain and Stress Management for People With Rheumatoid Arthritis

Wayne State University

NCT00088764

COMPLETED NA 273 participants

GIOP Prevention Among People With Rheumatoid Arthritis

University of North Carolina, Chapel Hill

NCT00609830

COMPLETED Phase 2 269 participants

Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate

Pfizer

NCT02996500

COMPLETED NA 266 participants

Actis Total Hip System 2 Year Follow-up

DePuy Orthopaedics

NCT02783274

COMPLETED Phase 2 266 participants

Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis

AstraZeneca

NCT01563978

COMPLETED 265 participants

The Value of Orencia in Rapidly Progressing Rheumatoid Arthritis

Bristol-Myers Squibb

NCT03331393

COMPLETED Phase 2 260 participants

Study to Evaluate Efficacy, Safety and Tolerability of JTE-051 in Subjects With Active Rheumatoid Arthritis

Akros Pharma

NCT02919475

COMPLETED Phase 2 254 participants

Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients

Can-Fite BioPharma

NCT00280917

COMPLETED Phase 2 251 participants

A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid Arthritis

Ablynx, a Sanofi company

NCT02287922

COMPLETED Phase 2 232 participants

A Multicentre Trial to Determine the Efficacy of AD 452 in RA Subjects.

Sosei

NCT00141934

COMPLETED 231 participants

Post-PMA Approval Study: 10 Year Follow-Up IDE Subjects

Corin

NCT00721994

COMPLETED Phase 1 223 participants

Pharmacokinetic Study to Compare the Blood Levels of Abatacept Manufactured at Lonza Biologics to the Blood Levels of Abatacept Manufactured at the Devens, Massachusetts (MA) Facility of Bristol-Myers Squibb

Bristol-Myers Squibb

NCT01439204

COMPLETED Phase 2 221 participants

Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy

UCB Pharma

NCT01242488

COMPLETED NA 210 participants

Clinical Investigation of the LCS® Complete Posterior Stabilized Mobile-bearing Total Knee System

DePuy Orthopaedics

NCT00487565

COMPLETED Phase 2 204 participants

A Study of P38 Inhibitor (4) Monotherapy in Patients With Active Rheumatoid Arthritis

Hoffmann-La Roche

NCT00303563

COMPLETED NA 201 participants

Breaking Implicit Bias Habits: An Individuation Pilot Study In Rheumatology

Brigham and Women's Hospital

NCT05116163

COMPLETED 200 participants

Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository

University of Alabama at Birmingham

NCT01070121

COMPLETED NA 200 participants

RAHelp.Org: An Online Self Management Program for Adults With Rheumatoid Arthritis

University of Missouri-Columbia

NCT00283855

COMPLETED Phase 2 189 participants

Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1)

Rigel Pharmaceuticals

NCT00326339

COMPLETED NA 181 participants

ROSA Robot Used in Total Knee Replacement Post Market Study

Zimmer Biomet

NCT03969654

COMPLETED 162 participants

Perioperative Flare in RA: Characterization of Clinical and Biological Features

Hospital for Special Surgery, New York

NCT02111057

COMPLETED NA 160 participants

NexGen TM Tibia Clinical Outcomes Study

Zimmer Biomet

NCT03272373

COMPLETED Phase 2 157 participants

Treating Rheumatoid Arthritis With Tripterygium Wilfordi Hook F or Sulfasalazine

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NCT00062465

COMPLETED 149 participants

A Clinical Investigation of ArComXL® Polyethylene in Total Hip Replacement

Zimmer Biomet

NCT00698152

COMPLETED 142 participants

Protocol For The Quantitation Of Pain In The Diagnosis Of Polymyalgia Rheumatica

Lahey Clinic

NCT00847236

COMPLETED Phase 2 141 participants

The Study of Abatacept in Combination With Etanercept

Bristol-Myers Squibb

NCT00162279

COMPLETED Phase 2 134 participants

Impact of Literacy Level on Patient Education and Health Among People With Arthritis

Brigham and Women's Hospital

NCT00023205

COMPLETED Phase 2 127 participants

INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs

Incyte Corporation

NCT00902486

COMPLETED NA 125 participants

"Learning About Biologics"-Rheumatoid Arthritis

Geisinger Clinic

NCT01721200

COMPLETED NA 124 participants

Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMo™ Component Training

Click Therapeutics

NCT05573685

COMPLETED Phase 2 119 participants

Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis

Bristol-Myers Squibb

NCT04186871

COMPLETED Phase 2 112 participants

A Study to Assess Immune Response Following Zoster Vaccination to Subjects With Rheumatoid Arthritis Receiving Tofacitinib or Placebo With Background Methotrexate

Pfizer

NCT02147587

COMPLETED NA 102 participants

2-Year Post-Approval Study to Investigate the Scandinavian Total Ankle Replacement System (STAR) Ankle Under Actual Conditions of Use

Encore Medical, L.P.

NCT01284283

COMPLETED Phase 2 100 participants

A Phase 2 Study to Evaluate the Efficacy and Safety of 60mg of MM-093 in Patients With Active Rheumatoid Arthritis

Merrimack Pharmaceuticals

NCT00458146

COMPLETED NA 100 participants

Robotic Arm Assisted Total Knee Arthroplasty

MAKO Surgical

NCT02058069

COMPLETED Phase 2 88 participants

Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab

AbbVie (prior sponsor, Abbott)

NCT01752855

COMPLETED Phase 1 80 participants

Vaccination Study of Abatacept (BMS-188667) for Normal Healthy Volunteers

Bristol-Myers Squibb

NCT00279734

COMPLETED NA 79 participants

Living Well With Rheumatoid Arthritis

Brigham and Women's Hospital

NCT00869349

COMPLETED Phase 2 78 participants

Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid Arthritis

Novartis

NCT00487825

COMPLETED 76 participants

Ankle Joint Replacement Outcomes Study

Smith & Nephew

NCT00503438

COMPLETED Phase 1 75 participants

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose CFZ533 in Rheumatoid Arthritis Patients

Novartis Pharmaceuticals

NCT02089087

COMPLETED Phase 2 75 participants

FolateScan in Autoimmune Disease

Mayo Clinic

NCT00588393

COMPLETED 74 participants

Lipids, Inflammation, and CV Risk in RA

Brigham and Women's Hospital

NCT02714881

COMPLETED Phase 1 74 participants

Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis

Pfizer

NCT03334851

COMPLETED Phase 3 69 participants

Triple III Comparison of Leflunomide Alone Versus Two DMARD Combinations in the Treatment of Rheumatoid Arthritis

University of Nebraska

NCT00579878

COMPLETED Phase 1 60 participants

A Multiple-dose Study of the Safety and Tolerability of REGN88(SAR153191) in Rheumatoid Arthritis Subjects

Regeneron Pharmaceuticals

NCT01011959

COMPLETED NA 55 participants

Effect of Exercise on the Disease Activity of Rheumatoid Arthritis

University of Nebraska

NCT00792675

← Previous Page 3 of 4 Next →

Phase Distribution

PhaseTrial count
Phase 1 33
Phase 2 44
Phase 3 25
Phase 4 7

Top Sponsors

Named interventions

Most-linked intervention names on Rheumatoid Arthritis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
27 trials
Abatacept Drug
7 trials
Methotrexate Drug
6 trials
Adalimumab Drug
6 trials
Hydroxychloroquine Drug
4 trials
Tofacitinib Drug
4 trials
Baricitinib Drug
4 trials
Placebo Other
4 trials

US sites by state

Facility locations filed on Rheumatoid Arthritis trials. A trial with sites in several states counts in each.

California 88 trials
Florida 70 trials
Texas 47 trials
Pennsylvania 46 trials
Arizona 43 trials
North Carolina 41 trials
Alabama 40 trials
Illinois 38 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Rheumatoid Arthritis page

199 registered trials, 37 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 37 Rheumatoid Arthritis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Zimmer Biomet sponsors the most Rheumatoid Arthritis trials on record, review their full trial history before evaluating a specific study. See Zimmer Biomet's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Rheumatoid Arthritis condition card totals 199 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.